PUXITATUG SAMROTECAN
UNII 396QL65J3Q

Substance Identification & Data

This profile provides standardized clinical and technical data for Puxitatug Samrotecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 396QL65J3Q.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2760250-80-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

396QL65J3Q

CAS Registry Number

2760250-80-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PUXITATUG SAMROTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C199096

National Cancer Institute reference terminology for clinical and research data.

INN ID

12513

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

MN-78

Identifier assigned by the United States Adopted Names Council.

Substance Type

Puxitatug Samrotecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Puxitatug Samrotecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Puxitatug Samrotecan

Common Names & Synonyms

AZD 8205 [WHO-DD]

Immunoglobulin G1, anti-(human B7 homolog 4 protein) (human monoclonal INT-016 γ1-chain), disulfide with human monoclonal INT-016 κ-chain, dimer, reduced, 214′′,214′′′,220,220′,226,226′,229,229′-octakis(thioether) with N-[31-(3-mercapto-2,5-dioxo-3-pyrrolidinyl)-1,29-dioxo-4,7,10,13,16,19,22,25-octaoxa-28-azahentriacont-1-yl]-L-valyl-N-[(9S)-9-ethyl-2,3,9,10,13,15-hexahydro-9-hydroxy-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl]-L-alaninamide

PUXITATUG SAMROTECAN [USAN]

immunoglobulin G1-kappa, anti-[Homo sapiens VTCN1 (V-set domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)], Homo sapiens monoclonal antibody; conjugated to a topoisomerase I inhibitor (gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens (IGHV4-34*01 (95.9%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo sapiens IGHG1*03 (100%), G1m3, nG1m1 CH1 R120, E12, M14 (CH1 R120 (214)(118-215), hinge 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-17*01 (96.8%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (153), V101 (191) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; 220, 214', 220'', 214''', 226, 226'', 229, 229'' -octakis (thioether) conjugated with N-[31-(3-mercapto-2,5-dioxo-3-pyrrolidinyl)-1,29-dioxo-4,7,10,13,16,19,22,25-octaoxa-28-azahentriacont-1-yl]- L-valyl-N-[(9S)-9-ethyl-2,3,9,10,13,15-hexahydro-9-hydroxy-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]-L-alaninamide)

puxitatug samrotecan [INN]